|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease.|
|Rapid review commissioned||01/09/2021|
|Rapid review completed||06/10/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that roxadustat not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations August 2022.